BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20126830)

  • 1. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor.
    Bouman HJ; van Werkum JW; Rudez G; Leebeek FW; Kruit A; Hackeng CM; Ten Berg JM; de Maat MP; Ruven HJ
    Thromb Haemost; 2010 Feb; 103(2):379-86. PubMed ID: 20126830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.
    Steinhubl SR; Oh JJ; Oestreich JH; Ferraris S; Charnigo R; Akers WS
    Thromb Res; 2008; 121(4):527-34. PubMed ID: 17631948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
    Rudez G; Bouman HJ; van Werkum JW; Leebeek FW; Kruit A; Ruven HJ; ten Berg JM; de Maat MP; Hackeng CM
    Circ Cardiovasc Genet; 2009 Oct; 2(5):515-21. PubMed ID: 20031628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
    Smith SM; Judge HM; Peters G; Armstrong M; Fontana P; Gaussem P; Daly ME; Storey RF
    Platelets; 2006 Jun; 17(4):250-8. PubMed ID: 16769602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
    Greenbaum AB; Ohman EM; Gibson CM; Borzak S; Stebbins AL; Lu M; Le May MR; Stankowski JE; Emanuelsson H; Weaver WD
    Am Heart J; 2007 Oct; 154(4):702-9. PubMed ID: 17892995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cangrelor: a novel P2Y12 receptor antagonist.
    Norgard NB
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1219-30. PubMed ID: 19604122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.
    Staritz P; Kurz K; Stoll M; Giannitsis E; Katus HA; Ivandic BT
    Int J Cardiol; 2009 Apr; 133(3):341-5. PubMed ID: 18485500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
    Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
    Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2Y receptor antagonists in thrombosis.
    Boeynaems JM; van Giezen H; Savi P; Herbert JM
    Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
    Storey RF; May JA; Heptinstall S
    Thromb Res; 2005; 115(4):301-7. PubMed ID: 15668190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.
    Akers WS; Oh JJ; Oestreich JH; Ferraris S; Wethington M; Steinhubl SR
    J Clin Pharmacol; 2010 Jan; 50(1):27-35. PubMed ID: 19779037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.
    Fontana P; Dupont A; Gandrille S; Bachelot-Loza C; Reny JL; Aiach M; Gaussem P
    Circulation; 2003 Aug; 108(8):989-95. PubMed ID: 12912815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the clinical development of cangrelor.
    Ueno M; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1069-77. PubMed ID: 20670184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.
    Schneider DJ
    Coron Artery Dis; 2016 Jan; 27(1):65-9. PubMed ID: 26444255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.